Heart Failure Clinical Trials in Durham, North Carolina

17 studies are recruiting for heart failure in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Alleviant ALLAY-HFrEF Study

   Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University Hospital, Durham, North Carolina

   Locations

   68 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT06812533 on ClinicalTrials.gov

2. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Durham, North Carolina

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

3. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Duke University, Durham, North Carolina

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

4. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Duke University Hospital, Durham, North Carolina

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

5. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

   Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   50 in total

   Run by

   Procyrion

   See if you can join NCT05677100 on ClinicalTrials.gov

6. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Duke University Health System, Durham, North Carolina

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

7. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, Durham, North Carolina

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

8. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

9. Alleviant ALLAY-HF Study

   Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

   Stage

   Not phased

   Ages

   40 and older

   Site

   Duke University Hospital, Durham, North Carolina

   Locations

   93 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT05685303 on ClinicalTrials.gov

10. Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

    There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of sup…

    Stage

    Phase 2

    Ages

    0 to 16

    Site

    Duke University Hospital, Durham, North Carolina

    Locations

    5 in total

    Run by

    Stanford University

    See if you can join NCT06080074 on ClinicalTrials.gov

11. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage

    Phase 2

    Ages

    40 to 84

    Site

    Duke University, Durham, North Carolina

    Locations

    117 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT06979362 on ClinicalTrials.gov

12. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UNC Medical Center, Durham, North Carolina

    Locations

    48 in total

    Run by

    Endotronix, Inc.

    See if you can join NCT05934487 on ClinicalTrials.gov

13. Splanchnic X: Splanchnic Nerve Block in Heart Failure With Reduced Ejection Fraction

    Heart failure (HF) affects more than 6 million adults in the U.S. alone, with increasing prevalence. Cardiovascular congestion with resultant limitation in physical activity is the hallmark of chronic and decompensated HF. The current HF physiologic model suggests that congestion is the result of v…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT06733012 on ClinicalTrials.gov

14. XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

    The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke University Medical Center, Durham, North Carolina

    Locations

    14 in total

    Run by

    XVIVO Perfusion

    See if you can join NCT06895070 on ClinicalTrials.gov

15. Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

    This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).

    Stage

    Phase 2

    Ages

    18 to 90

    Site

    Duke University Medical Center, Durham, North Carolina

    Locations

    3 in total

    Run by

    Baylor Research Institute

    See if you can join NCT03383419 on ClinicalTrials.gov

16. Supporting Health in Veterans With Heart Failure

    This study will test the effectiveness of a culturally-sensitive, telephone-based, tailored problem-solving intervention to improve physical and mental health in Veterans with heart failure (HF). Veterans will be recruited from VA clinics throughout the United States. As a component of this study, …

    Stage

    Not phased

    Ages

    18 and older

    Site

    VA Clinic - Durham, Durham, North Carolina

    Locations

    4 in total

    Run by

    Florida State University

    See if you can join NCT05839067 on ClinicalTrials.gov

17. BiVACOR® Total Artificial Heart Early Feasibility Study

    The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require m…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Duke University Hospital, Durham, North Carolina

    Locations

    4 in total

    Run by

    BiVACOR Inc.

    See if you can join NCT06174103 on ClinicalTrials.gov